ADC’s Phase II Data May Position ‘Lonca’ To Compete With Roche’s Polivy

12 Jun 2020

The antibody-drug conjugate yields a 48% overall and 24% complete response rate in a pivotal Phase II DLBCL study. The Swiss biotech hopes to compete with Polivy and is studying combo therapy with Imbruvica.

Lymphoma cancer cell - 3d rendering — ADC Therapeutics thinks Lonca has broad potential across lymphoma settings

ADC Therapeutics SARL is aiming to file a biologics license application for its antibody-drug conjugate loncastuximab tesirine (ADCT-402, aka Lonca) in the second half of 2020 following presentation of Phase II data on 12 June showing solid overall response rates in third-line diffuse large B-cell lymphoma patients, including in patients who haven’t responded to prior therapy.

The ADC, which combines a CD19-targeting antibody with a second-generation pyrrolobenzodiazepine dimer delivery mechanism, yielded a 48.3% (70/145) overall response rate in the 145-patient LOTIS 2 trial, along with a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

29 May 2025

• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.